When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MGTA - Magenta Therapeutics: Valuation Remains Under Pressure With Lack Of Catalysts But Promise Remains
Magenta Therapeutics Inc.
Note:The following article assumes you are familiar with my introductory article on Magenta.
Introduction
Magenta Therapeutics (MGTA) first came on my radar in June of last year before it began trading on Nasdaq. I was interested by their broad, practice-changing portfolio and the breadth of experience amongst their management team.
Shares opened at $15 and began trading in late June. Magenta was very vulnerable to a very weak 4Q '18 for all of biotech, dipping to all-time lows of $5/share. Magenta began a rally in January that was fortified with promising data